Please check your internet connection and try again.
# Ticagrelor (Brilinta)
## Overview
Ticagrelor is a direct-acting, reversibly binding P2Y12 platelet inhibitor.
## Primary Indications
* To reduce the thrombotic cardiovascular events (including cardiovascular death, myocardial infarction, and stroke) in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Adult Dosing
* **ACS:** 180 mg orally once, followed by 90 mg orally twice daily for up to 12 months.
* **History of MI (≥1 year post-ACS/MI):** Add-on to aspirin, 60 mg orally twice daily.
## Pediatric Dosing
Dosing for pediatric patients has not been established.
## Dose Adjustments
No specific dose adjustments are required for renal or hepatic impairment. Caution is advised in severe hepatic impairment.
## Contraindications
* Active pathological bleeding.
* History of transient ischemic attack (TIA) or stroke.
* Known hypersensitivity to ticagrelor or any of its components.
* Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin).
## Adverse Effects
* **Common:** Dyspnea, bleeding (major or minor), bradycardia, rash.
* **Serious:** Significant bleeding events, ventricular pauses, hyperkalemia.
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Avoid concomitant use with strong CYP3A4 inhibitors. Use with caution with other CYP3A4 substrates (e.g., statins, warfarin, certain calcium channel blockers), potentially requiring dose adjustments.
* **Antiplatelets/Anticoagulants:** Increased risk of bleeding.
* **Rh- darah-negative individuals receiving ticagrelor:** May experience symptomatic bradycardia.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor for bradycardia and assess clinical significance.
* Monitor potassium levels, especially in patients with other risk factors for hyperkalemia.
## Clinical Pearls
* Ticagrelor is a P2Y12 inhibitor with a faster onset and offset of action compared to clopidogrel.
* Dyspnea is a common side effect, often transient and not indicative of underlying cardiopulmonary disease.
* For ACS patients, ticagrelor is typically initiated as a 180 mg loading dose.
* The 60 mg twice-daily dose is indicated for long-term maintenance in patients with a history of MI.
* Discontinuation before completing the indicated duration may increase the risk of stent thrombosis, MI, or death.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making therapeutic decisions.*
